Regenerx Biopharmaceuticals, Inc (RGN)
General
RegeneRx Biopharmaceuticals, Inc. (the “Company”, “We”, “Us”, “Our”), is a biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, we are developing Thymosin beta 4 (“Tß4 ” ), a 43 amino acid peptide. Current research suggests that Tß4 may prove efficacious for multiple medical indications, therefore we are developing several Tß4-based therapeutic products. We hold over fifty world-wide patents and patent applications related to dermal, ophthalmic, and internal wounds and tissue repair, cardiac and neurological...
read more
RegeneRx Biopharmaceuticals, Inc. (the “Company”, “We”, “Us”, “Our”), is a biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, we are developing Thymosin beta 4 (“Tß4 ” ), a 43 amino acid peptide. Current research suggests that Tß4 may prove efficacious for multiple medical indications, therefore we are developing several Tß4-based therapeutic products. We hold over fifty world-wide patents and patent applications related to dermal, ophthalmic, and internal wounds and tissue repair, cardiac and neurological...
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
Contact Information:
| Business Address: | - |
| Mailing Address: | 3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 Business Address 3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 3019611992 |
| Phone: | 301-208-9191 |
| Fax: | 301-208-9194 |
| Website: | http://www.regenerx.com |
Company Details:
| Symbol: | RGN |
| SIC: | - |
| State location: | MD |
| Sector: | - |
| State of Inc: | DE |
| Employees: | 9 |
| Type: | AMEX |
Key executives:
| Name | Age | Position |
|---|---|---|
| Allan L. Goldstein Ph.D., | 74 | Founder, Chairman, Chairman of Medical and Scientific Advisory Board, Chief Scientific Advisor, Member of Nomination & Corp. Governance committee and Member of Stock Option Committee |
| C. Neil Lyons | 55 | Chief Financial Officer and Principal Accounting Officer |
| David R. Crockford | 67 | VP of Clinical and Regulatory Affairs |
| J. J. Finkelstein | 60 | Chief Exec. Officer, Pres, Director, Member of Nomination & Corp. Governance committee and Member of Stock Option Committee |
| Richard J. Hindin | 69 | Treasurer, Sec., Director, Member of Nomination & Corp. Governance committee, Member of Stock Option Committee and Member of Compensation Committee |
| Post # | Subject | Re | Name | Date |
|---|---|---|---|---|
| 1 | Ive known Richard Hindin for 50 years.I... | 0 | David Howard | September 15, 2008, 10:41AM |
| 2 | Here on this message board we are inviting... | 0 | Guest | September 15, 2008, 10:41AM |